J&J plans divestments after EU conditionally approves Guidant takeover
This article was originally published in Clinica
Executive Summary
Johnson & Johnson has finally crossed the halfway mark in its ongoing bid to take over rival Guidant. The healthcare conglomerate received the go-ahead from the EU on August 25 to purchase Guidant for the negotiated price of $25.4bn, on condition that J&J divested certain overlapping businesses.